title: Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects.
abstract: Quinacrine has been reported as an antiprion agent and proposed as an immediately applicable treatment for Creutzfeldt-Jakob disease (CJD). The authors report the results of an open compassionate procedure to which 32 CJD patients had access. In some genotypic subgroups, a slight but nonsignificant increase in survival was observed, likely due to biased inclusion of long-term surviving patients. There was no pathologic evidence of a beneficial effect of quinacrine treatment.
authors.affiliation: Raymond Escourolle Neuropathology Laboratory, INSERM U360, Salpêtrière Hospital, 47, bd de l'Hôpital, 75651 Paris Cedex 13, France. haik@chups.jussieu.fr
authors.forename: S
authors.initials: S
authors.lastname: Haïk
authors.forename: J P
authors.initials: JP
authors.lastname: Brandel
authors.forename: D
authors.initials: D
authors.lastname: Salomon
authors.forename: V
authors.initials: V
authors.lastname: Sazdovitch
authors.forename: N
authors.initials: N
authors.lastname: Delasnerie-Lauprêtre
authors.forename: J L
authors.initials: JL
authors.lastname: Laplanche
authors.forename: B A
authors.initials: BA
authors.lastname: Faucheux
authors.forename: C
authors.initials: C
authors.lastname: Soubrié
authors.forename: E
authors.initials: E
authors.lastname: Boher
authors.forename: C
authors.initials: C
authors.lastname: Belorgey
authors.forename: J J
authors.initials: JJ
authors.lastname: Hauw
authors.forename: A
authors.initials: A
authors.lastname: Alpérovitch
mesh_terms: D001921:Brain / Q000473:pathology; D007562:Creutzfeldt-Jakob Syndrome / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D018450:Disease Progression; D004341:Drug Evaluation; D006801:Humans; D011796:Quinacrine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016019:Survival Analysis; D017211:Treatment Failure
chemical_list: D011796:Quinacrine